Abstract
3-Nitrobenzanthrone (3-NBA), a suspected human carcinogen occurring in diesel exhaust and air pollution, and its human metabolite 3-aminobenzanthrone (3-ABA) were investigated for their ability to induce biotransformation enzymes in rat liver and the influence of such induction on DNA adduct formation by the compounds. Rats were treated (i.p.) with 0.4, 4, or 40 mg/kg body weight 3-NBA or 3-ABA. When hepatic cytosolic fractions from rats treated with 40 mg/kg body weight 3-NBA or 3-ABA were incubated with 3-NBA, DNA adduct formation, measured by 32P-postlabeling analysis, was 10-fold higher in incubations with cytosols from pretreated rats than with controls. The increase in 3-NBA-derived DNA adduct formation corresponded to a dose-dependent increase in protein levels and enzymatic activity of NAD(P)H:quinone oxidoreductase (NQO1). NQO1 is the major enzyme reducing 3-NBA in human and rat livers. Incubations of 3-ABA with hepatic microsomes of rats treated with 3-NBA or 3-ABA (40 mg/kg body weight) led to as much as a 12-fold increase in 3-ABA-derived DNA adduct formation compared with controls. The observed stimulation of DNA adduct formation by both compounds was attributed to their potential to induce protein expression and enzymatic activity of cytochromes P450 1A1 and/or -1A2 (CYP1A1/2), the major enzymes responsible for 3-ABA activation in human and rat livers. Collectively, these results demonstrate for the first time, to our knowledge, that by inducing hepatic NQO1 and CYP1A1/2, both 3-NBA and 3-ABA increase the enzymatic activation of these two compounds to reactive DNA adduct-forming species, thereby enhancing their own genotoxic potential.
Footnotes
-
This research was supported by Grants 303/05/2195 (to M.S.) from the Grant Agency of the Czech Republic, MSM0021620808 (to M.S.) and from the Ministry of Education of the Czech Republic, and by Cancer Research UK (to D.H.P. and V.M.A.).
-
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
-
doi:10.1124/dmd.106.009373.
-
ABBREVIATIONS: 3-NBA, 3-nitrobenzanthrone; 3-ABA, 3-aminobenzanthrone; COX, cyclooxygenase; cT, cycle threshold; dA-N6-ABA, 2-(2′-deoxyadenosin-N6-yl)-3-aminobenzanthrone; dG-N2-ABA, N-(2′-deoxyguanosin-N2-yl)-3-aminobenzanthrone; dG-C8-N-ABA, N-(2′-deoxyguanosin-8-yl)-3-aminobenzanthrone; DMSO, dimethyl sulfoxide; EROD, 7-ethoxyresorufin O-deethylation; MPO, myeloperoxidase; NQO1, NAD(P)H:quinone oxidoreductase; PVDF, polyvinylidene difluoride; NAT, N,O-acetyltransferase; SULT, sulfotransferase; P450, cytochrome P450; PAPS, 3′-phosphoadenosine-5′-phosphosulfate; HPLC, high-performance liquid chromatography; PCR, polymerase chain reaction.
-
↵
The online version of this article (available at http://dmd.aspetjournals.org) contains supplemental material.
- Received January 19, 2006.
- Accepted May 15, 2006.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|